Innovent Biologics Inc. (IVBXF)
Innovent Biologics Statistics
Share Statistics
Innovent Biologics has 1.64B shares outstanding. The number of shares has increased by 0.62% in one year.
| Shares Outstanding | 1.64B |
| Shares Change (YoY) | 0.62% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.52B |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -52.91 and the forward PE ratio is null. Innovent Biologics's PEG ratio is 0.97.
| PE Ratio | -52.91 |
| Forward PE | n/a |
| PS Ratio | 8.76 |
| Forward PS | n/a |
| PB Ratio | 4.34 |
| P/FCF Ratio | -44.01 |
| PEG Ratio | 0.97 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Innovent Biologics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3, with a Debt / Equity ratio of 0.29.
| Current Ratio | 3 |
| Quick Ratio | 2.78 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | -5.48 |
| Debt / FCF | -2.93 |
| Interest Coverage | -9.22 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.1M |
| Profits Per Employee | $-181.64K |
| Employee Count | 5,659 |
| Asset Turnover | 0.3 |
| Inventory Turnover | 1.17 |
Taxes
| Income Tax | -116.5M |
| Effective Tax Rate | 10.18% |
Stock Price Statistics
The stock price has increased by 21.34% in the last 52 weeks. The beta is 0.3, so Innovent Biologics's price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | 21.34% |
| 50-Day Moving Average | 5.4 |
| 200-Day Moving Average | 5.13 |
| Relative Strength Index (RSI) | 59.64 |
| Average Volume (20 Days) | 5.32K |
Income Statement
In the last 12 months, Innovent Biologics had revenue of 6.21B and earned -1.03B in profits. Earnings per share was -0.66.
| Revenue | 6.21B |
| Gross Profit | 5.07B |
| Operating Income | -909.21M |
| Net Income | -1.03B |
| EBITDA | -660.68M |
| EBIT | -1.05B |
| Earnings Per Share (EPS) | -0.66 |
Balance Sheet
The company has 10.05B in cash and 3.62B in debt, giving a net cash position of 6.43B.
| Cash & Cash Equivalents | 10.05B |
| Total Debt | 3.62B |
| Net Cash | 6.43B |
| Retained Earnings | -15.77B |
| Total Assets | 20.3B |
| Working Capital | 6.92B |
Cash Flow
In the last 12 months, operating cash flow was 147.81M and capital expenditures -1.38B, giving a free cash flow of -1.24B.
| Operating Cash Flow | 147.81M |
| Capital Expenditures | -1.38B |
| Free Cash Flow | -1.24B |
| FCF Per Share | -0.79 |
Margins
Gross margin is 81.69%, with operating and profit margins of -14.65% and -16.56%.
| Gross Margin | 81.69% |
| Operating Margin | -14.65% |
| Pretax Margin | -18.44% |
| Profit Margin | -16.56% |
| EBITDA Margin | -10.65% |
| EBIT Margin | -14.65% |
| FCF Margin | -19.91% |
Dividends & Yields
IVBXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for IVBXF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.06 |
| Piotroski F-Score | 3 |